Outcomes in patients with type 2 diabetes at different follow-up

Follow-up	Semaglutide cohort	Non-GLP1R agonist anti-diabetes medications cohort		HR (95% CI)
No prior history of CUD (n=25,820/cohort)				
1-year	0.21% (54)	0.48% (123)		0.40 (0.29–0.56)
2-year	0.41% (105)	0.72% (185)		0.52 (0.41–0.66)
3-year	0.57% (148)	0.91% (235)		0.58 (0.48–0.72)
Prior history of CUD (n=241/cohort)				
1-year	13.7% (33)	19.1% (46)		0.66 (0.42–1.03)
2-year	22.4% (54)	26.6% (64)		0.75 (0.52–1.08)
3-year	29.0% (70)	30.7% (74)		0.85 (0.61–1.18)

0.10 0.30 0.80 2.0 5.00
Hazard Ratio (HR)